Asparaginase erythrocyte companion diagnostic - ERYtech Pharma
Latest Information Update: 04 Feb 2015
At a glance
- Originator ERYtech Pharma
- Developer ERYtech Pharma; University of Texas M. D. Anderson Cancer Center
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Solid tumours